查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1654322

全球上皮瘤药物市场：市场规模、份额和趋势分析（按类型、药物类别、分销管道和地区）、按细分市场预测（2025-2030 年）

Epithelioma Treatment Market Size, Share & Trends Analysis Report By Type, By Drug Class (Hedgehog Pathway Inhibitors, Immune Checkpoint Inhibitors), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

上皮瘤药物市场的成长与趋势：

根据Grand View Research, Inc.的最新报告，全球上皮瘤治疗市场规模预计到2030年将达到97.3亿美元，2025年至2030年复合年增长率为10.4%。

皮肤癌，尤其是基底细胞癌（BCC）和鳞状细胞癌（SCC）发生率的增加是推动市场扩张的主要因素。根据美国癌症协会统计，预计2024年美国将出现约100,640例黑色素瘤新病例，其中男性约59,170例，女性约41,470例。此外，预计约有 8,290 人死亡，其中包括 5,430 名男性和 2,860 名女性。患病率的上升刺激了对先进治疗的需求，从而促进了市场的成长。

医疗技术的进步也扮演着重要角色。免疫查核点抑制剂（如Pembrolizumab、 Nivolumab）和标靶治疗（如用于治疗 BCC 的 vismodegib）等创新治疗方法的开发正在改变治疗选择，为患者带来新的希望并扩大市场机会。这些进展得到了良好的临床试验结果和 FDA核准的进一步支持，强调了这些治疗的有效性和安全性。

监管和政府措施对于塑造市场也至关重要。在美国，FDA 对有前景的治疗方法的快速核准流程有助于更快地获得新治疗方法。此外，在欧洲，欧洲药品管理局（EMA）等倡议为新药的开发和核准提供了重要支持。政府对癌症研究的资助以及增强早期发现和治疗的公众意识提升宣传活动进一步推动了市场成长。

上皮瘤药物市场：概述

  • 根据类型，基底细胞上皮瘤将占据市场主导地位，到 2024 年将占 61.0% 的份额。 BCC 是一种基底细胞上皮瘤，是世界上最常见的皮肤癌类型。
  • 根据药物类别，Hedgehog通路抑制剂有望在 2024 年获得超过 41.2% 的最大销售份额。这种优势归因于这些抑制剂在治疗 BCC 方面的功效、皮肤癌发病率的增加以及药物开发方面的最新重大进展。
  • 根据销售管道，医院药局部门在 2024 年引领市场，获得超过 51.8% 的显着收益占有率。
  • 预计北美上皮瘤药物市场将在 2024 年占据全球市场的主导地位，收益占有率为 37.5%，这主要得益于皮肤癌的高发病率和完善的医疗保健基础设施。

目录

第一章 分析方法及范围

第 2 章执行摘要

3. 上皮肿瘤药物市场：驱动因素、趋势与范围

  • 市场联动展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制分析
  • 商业环境分析
    • 产业分析：波特五力分析
    • PESTEL 分析

第 4 章上皮肿瘤治疗市场：按类型分類的业务分析

  • 按类型分類的市场占有率（2024 年和 2030 年）
  • 按类型分類的仪表板
  • 按类型分類的市场规模预测及趋势分析（2018-2030）
  • 基底细胞上皮瘤
  • 鳞状细胞肿瘤
  • 其他的

5. 上皮肿瘤药物市场：依药物类别的业务分析

  • 按药物类别分類的市场占有率（2024 年和 2030 年）
  • 药品类别仪表板
  • 依药物类别分類的市场规模预测及趋势分析（2018-2030年）
  • Hedgehog 路径抑制剂
  • 免疫查核点抑制剂
  • 化疗药物
  • 其他的

第 6 章 上皮肿瘤药物市场：按分销管道进行的业务分析

  • 按分销管道分類的市场占有率（2024 年和 2030 年）
  • 分销通路仪表板
  • 按分销管道分類的市场规模预测及趋势分析（2018-2030 年）
  • 医院药房
  • 零售药局
  • 其他的

第七章 上皮肿瘤药物市场：按地区分類的估计和趋势分析

  • 各地区市场占有率（2024 年及 2030 年）
  • 市场仪表板：按地区
  • 市场规模预测及趋势分析（2018-2030年）
  • 北美洲
    • 按国家/地区划分（2018-2030 年）
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 按国家/地区划分（2018-2030 年）
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 丹麦
    • 瑞典
  • 亚太地区
    • 按国家/地区划分（2018-2030 年）
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 按国家/地区划分（2018-2030 年）
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 按国家/地区划分（2018-2030 年）
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争格局

  • 参与企业概况
  • 企业市场分析
  • 公司分类
  • 战略地图
  • 公司简介/上市公司
    • Bristol-Myers Squibb Company
    • Merck &Co., Inc.
    • Novartis AG
    • Amgen Inc.
    • Pfizer Inc.
    • Sanofi
    • Johnson &Johnson Services, Inc.
    • F. Hoffmann-La Roche Ltd
Product Code: GVR-4-68040-446-0

Epithelioma Treatment Market Growth & Trends:

The global epithelioma treatment market size is expected to reach USD 9.73 billion by 2030, registering a CAGR of 10.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growing incidence of skin cancers, notably basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), is a major driver of market expansion. According to the American Cancer Society, the U.S. is expected to see approximately 100,640 new cases of melanoma in 2024, with around 59,170 in men and 41,470 in women. Additionally, melanoma is anticipated to cause about 8,290 deaths, including 5,430 men and 2,860 women. This escalating prevalence underscores the increasing demand for advanced treatments and contributes significantly to the market's growth.

Advancements in medical technology also play a crucial role. The development of innovative therapies, such as immune checkpoint inhibitors (e.g., pembrolizumab and nivolumab) and targeted therapies (e.g., vismodegib for BCC), has revolutionized treatment options, offering new hope for patients and expanding market opportunities. These advancements are further supported by positive clinical trial results and FDA approvals, which underscore the efficacy and safety of these treatments.

Regulatory bodies and government initiatives are also pivotal in shaping the market. In the U.S., the FDA's accelerated approval process for promising treatments facilitates faster access to new therapies. Additionally, initiatives like the European Medicines Agency (EMA) provide crucial support in developing and approving new drugs in Europe. Government funding for cancer research and public awareness campaigns are enhancing early detection and treatment, further driving market growth.

Epithelioma Treatment Market Report Highlights:

  • Based on type, basal cell epithelioma dominated the market and accounted for a share of 61.0% in 2024. BCC, a type of basal cell epithelioma, is the most common form of skin cancer globally.
  • Based on drug class, the hedgehog pathway inhibitors segment secured the largest revenue share of over 41.2% in 2024. This prominence is attributed to the efficacy of these inhibitors in treating BCC, the increasing incidence of skin cancers, and significant recent advancements in drug development.
  • Based on distribution channel, The hospital pharmacies segment led the market in 2024, capturing a substantial revenue share of over 51.8%.
  • North America epithelioma treatment market dominated the global market with a revenue share of 37.5% in 2024, largely fueled by the high incidence of skin cancers and a well-established healthcare infrastructure.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Drug Class
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Epithelioma Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Epithelioma Treatment Market: Type Business Analysis

  • 4.1. Type Market Share, 2024 & 2030
  • 4.2. Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 4.4. Basal Cell Epithelioma
    • 4.4.1. Basal Cell Epithelioma Market, 2018 - 2030 (USD Million)
  • 4.5. Squamous Cell Epithelioma
    • 4.5.1. Squamous Cell Epithelioma Market, 2018 - 2030 (USD Million)
  • 4.6. Others
    • 4.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Epithelioma Treatment Market: Drug Class Business Analysis

  • 5.1. Drug Class Market Share, 2024 & 2030
  • 5.2. Drug Class Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
  • 5.4. Hedgehog Pathway Inhibitors
    • 5.4.1. Hedgehog Pathway Inhibitors Market, 2018 - 2030 (USD Million)
  • 5.5. Immune Checkpoint Inhibitors
    • 5.5.1. Immune Checkpoint Inhibitors Market, 2018 - 2030 (USD Million)
  • 5.6. Chemotherapeutic Agents
    • 5.6.1. Chemotherapeutic Agents Market, 2018 - 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Epithelioma Treatment Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2024 & 2030
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Epithelioma Treatment Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030
  • 7.4. North America
    • 7.4.1. North America Epithelioma Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework
      • 7.4.2.3. Competitive Insights
      • 7.4.2.4. U.S. Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Framework
      • 7.4.3.3. Competitive Insights
      • 7.4.3.4. Canada Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Regulatory Framework
      • 7.4.4.3. Competitive Insights
      • 7.4.4.4. Mexico Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Epithelioma Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework
      • 7.5.2.3. Competitive Insights
      • 7.5.2.4. UK Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Framework
      • 7.5.3.3. Competitive Insights
      • 7.5.3.4. Germany Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Regulatory Framework
      • 7.5.4.3. Competitive Insights
      • 7.5.4.4. France Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Regulatory Framework
      • 7.5.5.3. Competitive Insights
      • 7.5.5.4. Italy Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Regulatory Framework
      • 7.5.6.3. Competitive Insights
      • 7.5.6.4. Spain Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.7. Norway
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Regulatory Framework
      • 7.5.7.3. Competitive Insights
      • 7.5.7.4. Norway Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.8. Denmark
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Regulatory Framework
      • 7.5.8.3. Competitive Insights
      • 7.5.8.4. Denmark Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.9. Sweden
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Regulatory Framework
      • 7.5.9.3. Competitive Insights
      • 7.5.9.4. Sweden Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Epithelioma Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework
      • 7.6.2.3. Competitive Insights
      • 7.6.2.4. Japan Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Regulatory Framework
      • 7.6.3.3. Competitive Insights
      • 7.6.3.4. China Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Regulatory Framework
      • 7.6.4.3. Competitive Insights
      • 7.6.4.4. India Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Regulatory Framework
      • 7.6.5.3. Competitive Insights
      • 7.6.5.4. South Korea Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.6. Australia
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Regulatory Framework
      • 7.6.6.3. Competitive Insights
      • 7.6.6.4. Australia Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Regulatory Framework
      • 7.6.7.3. Competitive Insights
      • 7.6.7.4. Thailand Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Epithelioma Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Regulatory Framework
      • 7.7.2.3. Competitive Insights
      • 7.7.2.4. Brazil Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Regulatory Framework
      • 7.7.3.3. Competitive Insights
      • 7.7.3.4. Argentina Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. MEA Epithelioma Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Regulatory Framework
      • 7.8.2.3. Competitive Insights
      • 7.8.2.4. South Africa Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Regulatory Framework
      • 7.8.3.3. Competitive Insights
      • 7.8.3.4. Saudi Arabia Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Regulatory Framework
      • 7.8.4.3. Competitive Insights
      • 7.8.4.4. UAE Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Regulatory Framework
      • 7.8.5.3. Competitive Insights
      • 7.8.5.4. Kuwait Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Bristol-Myers Squibb Company
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Merck & Co., Inc.
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Novartis AG
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Amgen Inc.
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Pfizer Inc.
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Sanofi
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Johnson & Johnson Services, Inc.
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. F. Hoffmann-La Roche Ltd
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global epithelioma treatment market, by region, 2018 - 2030 (USD Million)
  • Table 4 Global epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 5 Global epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 6 Global epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 7 North America epithelioma treatment market, by country, 2018 - 2030 (USD Million)
  • Table 8 North America epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 9 North America epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 10 North America epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 11 U.S epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 12 U.S epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 13 U.S Epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 14 Canada epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 15 Canada epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 16 Canada epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 17 Mexico epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 18 Mexico epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 19 Mexico epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 20 Europe epithelioma treatment market, by country, 2018 - 2030 (USD Million)
  • Table 21 Europe epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 22 Europe epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 23 Europe epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 24 UK epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 25 UK epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 26 UK Epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 27 Germany epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 28 Germany epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 29 Germany epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 30 France epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 31 France epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 32 France Epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 33 Italy epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 34 Italy epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 35 Italy epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 36 Spain epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 37 Spain epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 38 Spain epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 39 Norway epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 40 Norway epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 41 Norway Epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 42 Denmark epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 43 Denmark epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 44 Denmark epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 45 Sweden epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 46 Sweden epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 47 Sweden epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific epithelioma treatment market, by country, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 51 Asia Pacific epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 52 Japan epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 53 Japan epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 54 Japan epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 55 China epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 56 China epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 57 China epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 58 India epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 59 India epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 60 India epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 61 Australia epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 62 Australia epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 63 Australia epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 64 South Korea epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 65 South Korea epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 66 South Korea epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 67 Thailand epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 68 Thailand epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 69 Thailand epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 70 Latin America epithelioma treatment market, by country, 2018 - 2030 (USD Million)
  • Table 71 Latin America epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 72 Latin America epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 73 Latin America epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 74 Brazil epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 75 Brazil epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 76 Brazil epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 77 Argentina epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 78 Argentina epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 79 Argentina epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa Epithelioma treatment market, by country, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 83 Middle East & Africa epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 84 South Africa epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 85 South Africa epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 86 South Africa epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 89 Saudi Arabia epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 90 UAE epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 91 UAE epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 92 UAE epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 93 Kuwait epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 94 Kuwait epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 95 Kuwait epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Epithelioma treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Type and drug class outlook (USD Million)
  • Fig. 10 Distribution channel outlook (USD Million)
  • Fig. 11 Competitive landscape
  • Fig. 12 Epithelioma treatment market dynamics
  • Fig. 13 Epithelioma treatment market: Porter's five forces analysis
  • Fig. 14 Epithelioma treatment market: PESTLE analysis
  • Fig. 15 Epithelioma treatment market: Type segment dashboard
  • Fig. 16 Epithelioma treatment market: Type market share analysis, 2024 & 2030
  • Fig. 17 Basal cell epithelioma market, 2018 - 2030 (USD Million)
  • Fig. 18 Squamous cell epithelioma market, 2018 - 2030 (USD Million)
  • Fig. 19 Others market, 2018 - 2030 (USD Million)
  • Fig. 20 Epithelioma treatment market: Drug class segment dashboard
  • Fig. 21 Epithelioma treatment market: Drug class market share analysis, 2024 & 2030
  • Fig. 22 Hedgehog pathway inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 23 Immune checkpoint inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 24 Chemotherapeutic agents market, 2018 - 2030 (USD Million)
  • Fig. 25 Others market, 2018 - 2030 (USD Million)
  • Fig. 26 Epithelioma treatment market: Distribution channel segment dashboard
  • Fig. 27 Epithelioma treatment market: Distribution channel market share analysis, 2024 & 2030
  • Fig. 28 Hospital pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 29 Retail pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 30 Others market, 2018 - 2030 (USD Million)
  • Fig. 31 Epithelioma treatment market revenue, by region
  • Fig. 32 Regional marketplace: Key takeaways
  • Fig. 33 Regional marketplace: Key takeaways
  • Fig. 34 North America epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 35 U.S. country dynamics
  • Fig. 36 U.S. epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 37 Canada country dynamics
  • Fig. 38 Canada epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 39 Mexico country dynamics
  • Fig. 40 Mexico epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 41 Europe epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 42 UK country dynamics
  • Fig. 43 UK epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 44 Germany country dynamics
  • Fig. 45 Germany epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 46 France country dynamics
  • Fig. 47 France epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 48 Italy country dynamics
  • Fig. 49 Italy epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 50 Spain country dynamics
  • Fig. 51 Spain epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 52 Norway country dynamics
  • Fig. 53 Norway epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 54 Sweden country dynamics
  • Fig. 55 Sweden epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 56 Denmark country dynamics
  • Fig. 57 Denmark epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 58 Asia Pacific epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 59 Japan country dynamics
  • Fig. 60 Japan epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 61 China country dynamics
  • Fig. 62 China epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 63 India country dynamics
  • Fig. 64 India epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 65 Australia country dynamics
  • Fig. 66 Australia epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 67 South Korea country dynamics
  • Fig. 68 South Korea epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 69 Thailand country dynamics
  • Fig. 70 Thailand epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 71 Latin America epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 72 Brazil country dynamics
  • Fig. 73 Brazil epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 74 Argentina country dynamics
  • Fig. 75 Argentina epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 76 MEA epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 77 South Africa country dynamics
  • Fig. 78 South Africa epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 79 Saudi Arabia country dynamics
  • Fig. 80 Saudi Arabia epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 81 UAE country dynamics
  • Fig. 82 UAE epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 83 Kuwait country dynamics
  • Fig. 84 Kuwait epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 85 Company categorization
  • Fig. 86 Company market position analysis
  • Fig. 87 Strategic framework